The FDA grants "breakthrough" status to blood-cancer treatment ibrutinib, which is being...
The FDA grants "breakthrough" status to blood-cancer treatment ibrutinib, which is being developed by Pharmacyclics (PCYC +3.7%) and J&J (JNJ), for two rare types of lymphoma. The designation was created last year and could enable drug approval after just an expanded early stage study. The companies now plan to file for authorization of Ibrutinib by the end of the year. (PR)
Are you Bullish or Bearish on ?
Results for ()
Thanks for sharing your thoughts.
From other sites
In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibodyat Benzinga.com (Fri, 2:31PM)
Biotech Stock Roundup: Pharmacyclics Up on Buyout Rumors, Celgene Drug Label Expanded - Analyst Blogat Zacks.com (Thu, 11:07AM)
at Zacks.com (Thu, 9:00AM)
at Benzinga.com (Wed, 5:05PM)
at Benzinga.com (Wed, 2:47PM)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs